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Volumetric Modulated Arc Therapy followed by bilateral mastectomy  
for treating synchronous cancer and sarcoma — a rare case report
Jacek Gałecki1, Klaudia Bęczkowska1, Piotr Mężeński2
Purpose. Bilateral postmastectomy irradiation (BPMI) poses a challenge to radiotherapists. The difficulty lies whenever 
targets are large, irregular and lying at different depths. When breathing movements occur it is very hard to obtain 
homogenous dosing on such targets and also to not exceed those doses acceptable for at-risk organs, particularly 
the lungs and heart. The presented study is an example of using a single isocenter Volumetric Modulated Arc Therapy 
(VMAT) technique for a BPMI case.
Materials and methods. We report the case of a 66-year-old woman with simultaneous malignant sarcoma of the 
right breast and an invasive ductal carcinoma of the left breast. After modified radical mastectomy of the left breast 
and simple mastectomy of the right breast, the patient underwent adjuvant irradiation of the bilateral chest wall and 
left axillary and supraclavicular nodes region. Planning Target Volumes (PTV) and organs at risk (OAR) were deline-
ated on CT scans. A single isocenter VMAT plan was created. The radiotherapy consisted of 50 Gy delivered in 2 Gy 
per fraction to the left side and 56.5 Gy delivered in 2.25 Gy per fraction to the right side in 25 fractions, five times  
a week over 5 weeks. 
Results. The left and right CTV (Clinical Target Volume) received 90% of the prescribed dose in 100% of the CTV 
volume. The mean heart dose was 14.4 Gy and V25 for the heart was 8.9%. The mean lung dose was 16.6 Gy and the 
V20 for both lungs was 28.3%. The dose to the anterior wall area of the heart was exceeded according to established 
constraints, but was accepted. One session of irradiation lasted about four minutes during which the patient received 
595 monitor units. The treatment was carried out without interruption and complications. The early and late skin 
reaction was assessed as being second grade. After one year of follow-up, the patient did not present any serious 
side effects or recurrence. 
Conclusions. Synchronous irradiation of both sides of the chest wall after bilateral mastectomy with a single isocenter 
VMAT technique is possible and well tolerated. 
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Introduction
The clinical need for performing bilateral postmastec-
tomy chest wall irradiation occurs rarely because of the 
low incidence rate of synchronous bilateral breast cancer 
(BBC), at about 2% [1, 2]. Breast sarcoma (BS) is an even 
much rarer malignancy [3], thus the presented case of both 
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these cancers appearing together is rather an extreme coin-
cidence. Such situations require nonconventional manage-
ment using modern techniques of adjuvant radiotherapy. 
This study presents the use of one such technique; a single 
isocentre Volumetric Modulated Arc Therapy (VMAT) for 
bilateral synchronous postmastectomy irradiation. 
Case report 
Patient’s history and diagnoses
In November 2014, a 66-year old woman with type 2 
diabetes and arterial hypertension was admitted to emer-
gency care, suffering severe anaemia due to blood loss 
from a huge ulcerous right breast tumour. The patient had 
previously noticed a lump in her right breast about 1.5 years 
ago that had not been subject to diagnoses nor treatment, 
but this had rapidly grown within the last month. A family 
history of breast cancer was not reported. Breast palpation 
presented 15 cm bleeding and an ulcerous mass occupying 
the entire right breast which was mobile in relation to the 
pectoralis major muscle. No obvious lumps were found in 
the right axilla. The same examination revealed a palpable 
3.5 cm tumour in the lateral quadrants of the left breast. 
A palpable and movable 1.5 cm nodule was also found in 
the left axillary fossa. The computed tomography (CT) of 
the thorax confirmed a 17.5 × 10.3 cm polycyclic tumour in 
the right breast and a tumour on the border between the 
external quadrants of the left breast of 3.0 x 1.2 cm size and 
a 1.3 cm lymph node in the left axilla (Fig. 1).
The abdominal ultrasound and brain CT showed no 
obviously significant aberrations in other organs. Excisional 
biopsy of the right breast tumour demonstrated a malignant 
solitary fibrous tumour. Ultrasound-guided percutaneous 
biopsy of the left breast lesion showed an invasive ductal 
carcinoma. Based on histopathological diagnosis and clinical 
stage, the patient was qualified for surgery of both breast 
lesions at the same time. Modified radical mastectomy of 
the left breast and simple mastectomy of the right breast 
was thereby performed. The final pathological examination 
showed in the left breast: — an invasive ductal carcinoma 
NST, a histological grade 2 (G2) rating, pT2 (3.0 cm in its 
greatest dimension) and pN3c (four nodes involved out of 
twelve excised) — oestrogen receptor-positive, progestero-
ne receptor — negative, HER2 — negative and Ki67 — 10%. 
In the right breast, the diagnosis of a malignant solitary 
fibrous tumour was confirmed (at its greatest dimension of 
21.0 cm). Surgical margins were free of malignancy. 
Because of concomitant diseases and established ische-
mic heart disease, as shown by echocardiography, the pa-
tient was not qualified for adjuvant chemotherapy but was 
given adjuvant radiotherapy and hormone-therapy with 
Tamoxifen. Due to the high risk of the loco-regional tumours 
recurring, the patient was synchronously irradiated on both 
sides of the chest wall and on the left axillary and supracla-
vicular lymph nodes region. The radiotherapy consisted of 
50 Gy delivered in 2 Gy per fraction to the left side and 56.5 
Gy delivered in 2.25 Gy per fraction to the right side, five 
times a week over 5 weeks. The early and late skin reaction 
was assessed by the RTOG scale [4, 5].
Imaging and treatment planning
CT imaging was performed on the treated patient in 
a supine position with both arms above the head. During 
the CT scans and in subsequent radiation therapy, a 1 cm 
tissue equivalent bolus was added around the patient chest 
wall. On the left side, an additional wax bolus was added 
to obtain a homogenous dose distribution on the irregular 
shaped chest wall (Fig. 2). Using CT cross sections, the Cli-
nical Target Volume (CTV) for both sides were delineated. 
The right side CTV included only the chest wall, whilst the 
left side CTV included the chest wall and supraclavicular 
and axillary lymph nodes. Planning Target Volume (PTV) 
was established by adding an isotropic margin of 0.6 cm to 
the CTV (Fig. 3). The organs at risk (OAR) defined by CT were: 
both lungs, heart, coronary arteries and spinal cord. Our own 
protocol for delineating CTV and OAR dose were based on 
the Danish Breast Cancer Cooperative Group, QUANTEC and 
ESTRO consensus guidelines [6–11]. The mean dose to the 
heart should be below 26 Gy and V25 volume below 10%. 
In the lungs, the V20 volume should be below 30 % and the 
mean lung dose less than 20 Gy, whilst the maximum dose 
to spinal cord should be below 50 Gy. Coronary arteries were 
schematically delineated as an area of the anterior wall of 
the heart (Fig. 3) [12]. A single isocentric VMAT plan was 
prepared by a medical physicist using the Eclipse treatment 
planning system (version 10). The treatment plan was based 
Figure 1. Computed tomography before surgery
50
on two 6 MV photon arcs (clockwise and anti-clockwise). 
Each arc was divided into upper and lower subfields (Fig. 3). 
The Analytical Anisotropic Algorithm dose calculation algo-
rithm was used. A simultaneous optimization for both sides 
with different doses per fraction was performed. 
Quality Assurance (QA) of the treatment plan
This was performed on the Varian EPID (Electronic Portal 
Imaging Devices). The differences between calculated and 
measured dose distributions were evaluated by the gamma 
parameter [13]. 
Treatment delivery with image-guidance 
The patient was treated with the TrueBeam linac acce-
lerator. The daily patient setup was verified by planar setup 
fields and Cone Beam Computed Tomography (CBCT). 
Results 
For the target volumes CTV and PTV the following dose 
distribution parameters are presented. 
The Left CTV 90% and 95% of the prescribed dose cover 
100% and 98.9% of the structure with a standard deviation 
of dose (STD) values at 2.4%. For left PTV 90% and 95% of 
the prescribed dose cover 99.3% and 94% volume of the 
structure, STD 2.8%. For right CTV 90% and 95% of the pre-
scribed dose cover 100% and 98.2% of the structure volume 
and cover 97.6% and 90.7% of the PTV volume. The STD 
values are 2.4% for the CTV and 3.4% for the PTV (Figs. 4–6). 
The mean heart dose was 14.4 Gy and theV25 for heart 
was 8.9%. The mean lungs dose was 16.6 Gy, and theV20 
for both lungs was 28.3%. The maximum dose to the spinal 
cord was 21 Gy. The additional organ at risk “the coronary 
arteries” was involved in a optimisation process to reduce 
the dose to the heart. In the coronary arteries structure, the 
volume of 20 Gy was minimized. In the plan to pass the QA 
verification, the gamma parameter (3%, 3 mm) value was 
96.5% (tolerance 95%). Unfortunately the dose to the heart’s 
anterior wall area was exceeded, according to established 
constraints, but was accepted (Fig. 7; Tab. I). One session of 
irradiation lasted about four minutes during which the pa-
tient received 595 monitor units. The treatment was carried 
out without interruptions and complications. The early and 
late skin reaction was assessed as being second grade (Fig. 8). 
After one year of follow-up, the patient did not present any 
serious side effects or recurrence. 
Discussion
Postmastectomy bilateral irradiation (PMBI) constitu-
tes a challenge for the radiotherapist. Due to large and 
Figure 2. The patient in a supine position with a 1 cm bolus covering 
the chest wall (A); CT cross section with a 1cm bolus (b1) and 





Figure 3. Therapeutic arc arrangements and contours of the target 
volumes and OAR. Pink-right CTV, red-right PTV, magenta-left CTV, 
cyan-left PTV. Orange-lung’s, dark green-heart, light green-coronary 
arteries, blue-spinal cord (A); View of therapeutic fields (B)
51
Figure 4. Dose distribution. A. Right side PTV isodose level from 90% of prescribed dose (5062,5 cGy). B. Left side PTV isodose level from 90% of 
prescribed dose (4500 cGy)
A B
A B
Figure 5. Dose distribution of: A. 20 Gy and more B. 10 Gy and more
Figure 6. Dose Volume Histogram of the CTV (Clinical Target Volume) 
and PTV (Planning Target Volume) in the presented irradiated patient. 
CTV L and PTV L — left side target volumes; CTV R and PTV R — right 
side target volumes
Figure 7. Dose Volume Histogram of the organs at risk (OAR) in the 
presented irradiated patient
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irregular targets lying at different depths, in conjunction 
with breathing movements, it is very difficult to achieve 
properly homogenous dosing onto targets and not to exce-
ed acceptable doses for OAR; particularly the lungs and 
heart. Nowadays, the most frequently used postmastectomy 
irradiation techniques are Mono Isocentric Conformal Ra-
diotherapy, Intensity Modulated Radiation Therapy (IMRT) 
or Volumetric Modulated Arc Therapy (VMAT) [14]. Due to 
the extensive area that requires radiation treatment use of 
single-isocenter IMRT is not possible due to the limitations 
of maximum size of the therapeutic field. Nevertheless, 
the use of IMRT plans based on two isocenters result in 
a summation of the dose in the sternum region to 75 Gy. 
That is why, VMAT technique with single-isocenter was used. 
Besides, using conventional IMRT techniques, the irradiation 
time is prolonged due to two separate isocentres used. In 
our case, one session of irradiation lasted only four minutes. 
VMAT delivers the same radiation doses faster with less 
monitor units than for conventional IMRT, as well as ena-
bling organs at risk to be often better shielded/spared [15]. 
However, due care and attention are required for IMRT or 
VMAT techniques, which are only used for specific clinical 
circumstances because of the larger areas of normal tissues 
exposed to small doses compared to conformal methods. 
The presented patient underwent a left radical mastectomy 
because of cancer, but only a simple mastectomy on the 
right side due to sarcoma was performed because this type 
of neoplasm spreads mostly through blood vessels and 
does not require axillary dissection. For such reasons the 
left side chest wall and supraclavicular and axillary region 
were together exposed to irradiation, but only the right side 
chest wall received such irradiation. These two sides of treat-
ment with a different diagnosis and high risk of recurrence, 
required fast irradiation treatment because of concomitance 
diseases and so the patient was not qualified for adjuvant 
chemotherapy. The modern technique of VMAT irradiation 
was chosen so as to permit the doses to be differentiated 
according to the diagnosis and where both sides could be 
simultaneously treated. On the left and right sides, total 
doses was respectively given of 50 Gy and 56.25 Gy over 
5 weeks (25 fractions). The most serious late complication 
after such irradiation is cardiotoxicity. According to Darby 
et al. the risk of serious cardiac events begins within a few 
years after the heart has been exposed to ionizing irradia-
tion, which increases linearly with the mean dose to the 
heart by 7.4% per gray, with no apparent threshold and 
continues on for at least 20 years after the irradiation [16]. 
For this reason, the different and sophisticated methods of 
irradiation using the deep inspiration breath holding tech-
nique should be used to reduce the dose for the heart and 
coronary vessels, thus diminishing the risk of cardiotoxicity. 
This is why, special attention should be given to cardiac func-
tion during patient follow up. Unfortunately, outcomes for 
treating breast sarcoma patients have not improved much 
over the last fifty years. Disease free survival at 5 years in 
a major series of 63 breast sarcoma patients treated at the 
Royal Marsden Hospital in London and the Mater Adult 
Hospital in Australia between 1996–2006 as well as 113 
breast sarcomas patients treated at the Warsaw Center for 
Oncology Institute between 1947–1997 were similar 42% 
and 49% respectively [17, 18]. Postsurgical irradiation with 
modern techniques appears to be helpful in such difficult 
clinical circumstances as in our case, thereby delivering 
a better chance for curative treatment. 
Table I. Doses in the organs at risk




Heart V25 = 8.9% V25 < 10%
Dmean = 14.4 Gy Dmean < 26 Gy
Dmean (desirable) < 10 Gy
Lungs V20 = 28.3% V20 < 30%
Dmean = 16.6 Gy Dmean < 20 Gy
Coronary artery V20 = 57.5% V20 < 40%
Dmean = 23.8 Gy Dmean < 17 Gy




Synchronous irradiation of both sides of the chest wall 
after bilateral mastectomy with a single isocenter VMAT 
technique is possible and well tolerated. 
Conflict of interest: none declared
Jacek Gałecki, MD, PhD
Department of Radiotherapy I
Maria Skłodowska-Curie Memorial Cancer Centre  




Received: 3 Jan 2017 
Accepted: 20 Mar 2017
References
1. Jobsen JJ, van der Palen J, Ong F et al. Synchronous, bilateral 
breast cancer: prognostic value and incidence. Breast 2003; 12: 83– 
–88.
2.  Yamauchi C, Mitsumori M, Nagata Y et al. Bilateral breast-conserving 
therapy for bilateral breast cancer: results and consideration of radiation 
technique. Breast Cancer 2005; 12: 135–139.
3. Grabowski J, Salzstein SL, Sadler GR et al. Malignant phyllodes tumors: 
a review of 752 cases. Am Surg 2007; 73: 967–969.
4. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy 
Oncology Group (RTOG) and the European Organization for Research 
and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 
31: 1341–1346.
5. Hoeller U, Tribius S, Kuhlmey A et al. Increasing the rate of late toxicity 
by changing the score? A comparison of RTOG/EORTC and LENT/SOMA 
scores. Int J Radiat Oncol Biol Phys 2003; 55: 1013–1018.
6. Dijkema IM, Hofman P, Raaijmakers CP et al. Loco-regional conformal 
radiotherapy of the breast: delineation of the regional lymph node 
clinical target volumes in treatment position. Radiother Oncol 2004; 
71: 287–295.
7. Nielsen MH, Berg M, Pedersen AN et al. Delineation of target volumes 
and organs at risk in adjuvant radiotherapy of early breast cancer: 
national guidelines and contouring atlas by the Danish Breast Cancer 
Cooperative Group. Acta Oncol 2013; 52: 703–710.
8. Offersen BV, Boersma LJ, Kirkove C et al. ESTRO consensus guideline on 
target volume delineation for elective radiation therapy of early stage 
breast cancer. Radiother Oncol 2015; 114: 3–10.
9. Feng M, Moran JM, Koelling T et al. Development and validation of 
a heart atlas to study cardiac exposure to radiation following treatment 
for breast cancer. Int J Radiat Oncol Biol Phys 2011; 79: 10–18.
10. Kong FM, Ritter T, Quint DJ et al. Consideration of dose limits for organs 
at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, 
esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol 
Phys 2011; 81: 1442–1457.
11. Kirkpatrick JP, van der Kogel AJ, Schultheiss TS. Radiation dose–vol-
ume effects in the spinal cord. Int J Radiat Oncol Biol Phys 2010; 76 
(3 Suppl): S42–S49.
12. Tan W, Liu D, Xue C et al. Anterior myocardial territory may replace the 
heart as organ at risk in intensity-modulated radiotherapy for left-sided 
breast cancer. Int J Radiat Oncol Biol Phys 2012; 82: 1689–1697.
13. Depuydt T, Van Esch A, Huysken DP. A quantitative evaluation of IMRT 
dose distributions: refinement and clinical assessment of the gamma 
evaluation. Radiother Oncol 2002; 62: 309–319.
14. Seppälä J, Heikkilä J, Myllyoja K et al. Volumetric modulated arc therapy 
for synchronous bilateral whole breast irradiation — A case study. 
Rep Pract Oncol Radiother 2015; 20: 398–402.
15. Popescu CC, Olivotto IA, Beckham WA et al. Volumetric modulated arc 
therapy improves dosimetry and reduces treatment time compared 
to conventional intensity-modulated radiotherapy for locoregional 
radiotherapy of left-sided breast cancer and internal mammary nodes. 
Int J Radiat Oncol Biol Phys 2010; 76: 287–295.
16. Darby SC, Ewertz M, McGale P et al. Risk of ischemic heart disease in 
women after radiotherapy for breast cancer. N Engl J Med 2013; 368: 
987–998.
17. Pencavel T, Allan CP, Thomas JM et al. Treatment for breast sarcoma: 
A large, single-centre series. Eur J Surg Oncol 2011; 37: 703–708.
18. Niwińska A, Chmielewski R. Fifty years experience in the treatment 
of breast sarcomas and carcinomas at the Institute of Oncology 
in Warsaw. An analysis of 113 cases. Nowotwory 2000; 50 (Suppl 2): 
S54–60.
